UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2022
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
GlaxoSmithKline plc
 
Results of 22nd Annual General Meeting
 
GlaxoSmithKline plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 4 May 2022. Shareholders were able to join virtually via Lumi, Zoom and in person at the meeting held at the Sofitel Hotel in Terminal 5 Heathrow.
 
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
 
The table below shows the results of the poll on all 28 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 28 March 2022, which is available on GSK's website at www.gsk.com.
 
Resolution
Total votes for(1)(2)
%
Total votes against(2)
%
Total votes cast
Votes withheld(3)
1
Receive and adopt the 2021 Annual Report
3,524,582,633
99.01
35,137,552
0.99
3,559,720,185
11,843,164
2
Approve the Annual report on remuneration  
3,240,737,115
91.05
318,510,405
8.95
3,559,247,520
12,317,062
3
Approve the Remuneration Policy
2,197,755,545
61.76
1,360,515,540
38.24
3,558,271,085
13,294,793
4
Election of Dr Anne Beal
3,546,443,179
99.55
16,055,842
0.45
3,562,499,021
9,042,781
5
Election of Dr Harry Dietz
3,545,845,271
99.54
16,469,238
0.46
3,562,314,509
9,224,475
6
Re-election of Sir Jonathan Symonds
3,482,374,837
97.76
79,898,313
2.24
3,562,273,150
9,274,730
7
Re-election of Dame Emma Walmsley
3,555,195,651
99.79
7,564,971
0.21
3,562,760,622
8,806,465
8
Re-election of Charles Bancroft
3,503,934,446
98.36
58,393,472
1.64
3,562,327,918
9,214,474
9
Re-election of Vindi Banga
3,483,288,426
97.79
78,881,291
2.21
3,562,169,717
9,373,841
10
Re-election of Dr Hal Barron
3,546,018,185
99.54
16,347,031
0.46
3,562,365,216
9,173,855
11
Re-election of Dr Vivienne Cox
3,531,865,048
99.14
30,474,324
0.86
3,562,339,372
9,204,548
12
Re-election of Lynn Elsenhans
3,476,281,291
97.58
86,142,909
2.42
3,562,424,200
9,118,541
13
Re-election of Dr Laurie Glimcher
3,556,622,114
99.84
5,547,225
0.16
3,562,169,339
9,375,696
14
Re-election of Dr Jesse Goodman
3,555,655,121
99.82
6,515,409
0.18
3,562,170,530
9,367,820
15
Re-election of Iain Mackay
3,551,784,186
99.71
10,432,989
0.29
3,562,217,175
9,333,434
16
Re-election of Urs Rohner
3,410,175,068
95.74
151,806,419
4.26
3,561,981,487
9,561,680
17
Re-appointment of the auditor
3,557,280,686
99.84
5,797,033
0.16
3,563,077,719
8,481,780
18
Remuneration of the auditor
3,555,233,064
99.86
5,000,395
0.14
3,560,233,459
11,338,880
19
Authority for the company to make donations to political organisations and incur political expenditure
3,493,409,287
98.64
48,161,797
1.36
3,541,571,084
30,003,446
20
Authority to allot shares
3,430,993,149
96.35
130,127,471
3.65
3,561,120,620
10,593,875
21
Disapplication of pre-emption rights - general power(4)
3,460,375,320
97.24
98,220,644
2.76
3,558,595,964
12,963,416
22
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)
3,404,168,390
95.65
154,942,194
4.35
3,559,110,584
12,448,092
23
Authority for the company to purchase its own shares(4)
3,517,497,794
98.79
43,085,674
1.21
3,560,583,468
10,990,502
24
Exemption from statement of senior statutory auditor's name
3,523,554,816
99.59
14,359,955
0.41
3,537,914,771
33,655,391
25
Authority for reduced notice of a general meeting other than an AGM(4)
3,331,432,180
93.62
227,176,994
6.38
3,558,609,174
12,950,914
26
Approve the Share Save Plan 2022
3,508,449,940
98.62
49,235,709
1.38
3,557,685,649
13,896,262
27
Approve the Share Reward Plan 2022
3,516,666,377
98.86
40,690,090
1.14
3,557,356,467
14,160,284
28
Approve the adoption of new Articles of Association(4)
3,549,030,121
99.80
6,964,097
0.20
3,555,994,218
15,501,889
 
Resolution 3 - Approval of the Remuneration Policy
 
The Company was pleased that the new remuneration policy was supported in a vote at today's Annual General Meeting.  It also notes that a significant minority were not able to support the new policy at this time. The Company undertook an in-depth consultation process with the majority of its largest shareholders in developing the revised policy and will continue to engage to ensure it fully understands the views of all shareholders on these matters, and to continue to explain the rationale for the changes.
 
Notes:
 
(1)   The "for" votes include those giving the Chair discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.
(2)    Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3)    A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(4)    Indicates Special Resolutions requiring a 75% majority.
 
 
The following table provides further information on participation in the AGM:
 
 
 
GSK's
Twenty second
AGM
(Hybrid meeting)
(2022)
 
GSK's
Twenty first
AGM
(Virtual meeting)
(2021)
Issued share capital (excluding Treasury Shares)
5,083,974,547
5,031,444,276
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
70.25%
70.11%
Total shareholder population
89,764
100,906
Total number of proxies lodged
5,343
6,089
Number of shareholders in attendance
93 in person
68 participated virtually
142 participated virtually
% of shareholders who lodged proxies
5.95%
6.03%
 
The above poll results will shortly be available on the company's website at www.gsk.com. In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 
 
V A Whyte
Company Secretary
4 May 2022
 
 
 
 
 
 
SIGNATURES
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: May 04, 2022
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc
 
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.